Effect of Fluocinolone Acetonide (0.1%) Treatment in Oral Lichen Planus Patients on Salivary Lactoferrin Levels and Candida Colonization: a Prospective Study

Overview

Journal BMC Oral Health

Publisher Biomed Central

Specialty Dentistry

Date 2022 Mar 5

PMID 35246095

Authors

Nuttapong Saengprasittichok

Jeerus Sucharitakul

Oranart Matangkasombut

Chanwit Prapinjumrune

Affiliations

Soon will be listed here.

Abstract

Background: Although topical steroids are an effective treatment for oral lichen planus, they can have suppressive effects on oral immunity and predispose the patients to Candida overgrowth. Lactoferrin is a crucial local immunity protein in the oral cavity with important antimicrobial activity. The aim of this study was to prospectively investigate salivary lactoferrin secretion levels and Candida colonization in oral lichen planus patients treated with fluocinolone acetonide 0.1% in orabase.

Methods: Saliva samples were collected from 15 oral lichen planus subjects who had never received topical steroid treatment prior to this study and 15 healthy volunteers to determine their salivary lactoferrin levels using an enzyme-linked immunosorbent assay and to investigate the presence of oral Candida species at baseline and 3 months after treatment with fluocinolone acetonide 0.1% in orabase. Statistical analysis was performed to compare lactoferrin secretion and Candida colonization levels between the groups using the Mann-Whitney U test for independent data or the Wilcoxon Signed-Rank test for paired data.

Results: The salivary lactoferrin secretion level was not significantly different between the control group and oral lichen planus patients or between before and after treatment with fluocinolone acetonide 0.1% in orabase (P > 0.05). Candida was detected in 11 (73.33%) healthy volunteers, 8 (53.33%) oral lichen planus patients before treatment, and 9 (60%) oral lichen planus patients after treatment with fluocinolone acetonide 0.1% in orabase. There was no significant difference in Candida counts between the groups (P > 0.05).

Conclusion: Our study indicates that using fluocinolone acetonide 0.1% in orabase to treat oral lichen planus for 3 months did not affect salivary lactoferrin protein secretion or Candida carriage. Trial registration The trial was registered at the Thai Clinical Trials Registry (TCTR identifier: TCTR20200723002).

Citing Articles

A Decadal Bibliometric Analysis on the Therapeutic Strategies in Oral Lichen Planus.

Srivastava K, Saini R, Lin G, Heboyan A, Shrivastava D Health Sci Rep. 2025; 8(2):e70403.

PMID: 39897464 PMC: 11779748. DOI: 10.1002/hsr2.70403.

Impact of exosomes in oral lichen planus: A review with insights into pathogenesis and biomarkers.

Kumar R, Joghee S, Puttaraju M J Dent Sci. 2024; 19(3):1320-1327.

PMID: 39035313 PMC: 11259680. DOI: 10.1016/j.jds.2024.05.017.

Factors involved in the remission of oral lichen planus treated with topical corticosteroids.

Wongpakorn P, Chantarangsu S, Prapinjumrune C BDJ Open. 2024; 10(1):34.

PMID: 38719818 PMC: 11078943. DOI: 10.1038/s41405-024-00217-4.

References

Garcia-Montoya I, Cendon T, Arevalo-Gallegos S, Rascon-Cruz Q . Lactoferrin a multiple bioactive protein: an overview. Biochim Biophys Acta. 2011; 1820(3):226-36. PMC: 7127262. DOI: 10.1016/j.bbagen.2011.06.018. View

Mizuhashi F, Koide K, Toya S, Takahashi M, Mizuhashi R, Shimomura H . Levels of the antimicrobial proteins lactoferrin and chromogranin in the saliva of individuals with oral dryness. J Prosthet Dent. 2014; 113(1):35-8. DOI: 10.1016/j.prosdent.2013.12.028. View

Challacombe S . Haematological abnormalities in oral lichen planus, candidiasis, leukoplakia and non-specific stomatitis. Int J Oral Maxillofac Surg. 1986; 15(1):72-80. DOI: 10.1016/s0300-9785(86)80013-8. View

Malone H, Nicholl H, Coyne I . Fundamentals of estimating sample size. Nurse Res. 2016; 23(5):21-5. DOI: 10.7748/nr.23.5.21.s5. View

Thongprasom K, Luengvisut P, Wongwatanakij A, Boonjatturus C . Clinical evaluation in treatment of oral lichen planus with topical fluocinolone acetonide: a 2-year follow-up. J Oral Pathol Med. 2003; 32(6):315-22. DOI: 10.1034/j.1600-0714.2003.00130.x. View

Vila T, Sultan A, Montelongo-Jauregui D, Jabra-Rizk M . Oral Candidiasis: A Disease of Opportunity. J Fungi (Basel). 2020; 6(1). PMC: 7151112. DOI: 10.3390/jof6010015. View

Nadig S, Timmasandra Ashwathappa D, Manjunath M, Krishna S, Annaji A, Shivaprakash P . A relationship between salivary flow rates and Candida counts in patients with xerostomia. J Oral Maxillofac Pathol. 2017; 21(2):316. PMC: 5596688. DOI: 10.4103/jomfp.JOMFP_231_16. View

Lodi G, Scully C, Carrozzo M, Griffiths M, Sugerman P, Thongprasom K . Current controversies in oral lichen planus: report of an international consensus meeting. Part 1. Viral infections and etiopathogenesis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005; 100(1):40-51. DOI: 10.1016/j.tripleo.2004.06.077. View

Thongprasom K, Dhanuthai K . Steriods in the treatment of lichen planus: a review. J Oral Sci. 2008; 50(4):377-85. DOI: 10.2334/josnusd.50.377. View

10.

Zarember K, Sugui J, Chang Y, Kwon-Chung K, Gallin J . Human polymorphonuclear leukocytes inhibit Aspergillus fumigatus conidial growth by lactoferrin-mediated iron depletion. J Immunol. 2007; 178(10):6367-73. DOI: 10.4049/jimmunol.178.10.6367. View

11.

Cheng Y, Gould A, Kurago Z, Fantasia J, Muller S . Diagnosis of oral lichen planus: a position paper of the American Academy of Oral and Maxillofacial Pathology. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016; 122(3):332-54. DOI: 10.1016/j.oooo.2016.05.004. View

12.

Roca-Ferrer J, Mullol J, Perez M, Xaubet A, Molins L, De Haro J . Effects of topical glucocorticoids on in vitro lactoferrin glandular secretion: comparison between human upper and lower airways. J Allergy Clin Immunol. 2000; 106(6):1053-62. DOI: 10.1067/mai.2000.110476. View

13.

Andres M, Acosta-Zaldivar M, Fierro J . Antifungal Mechanism of Action of Lactoferrin: Identification of H+-ATPase (P3A-Type) as a New Apoptotic-Cell Membrane Receptor. Antimicrob Agents Chemother. 2016; 60(7):4206-16. PMC: 4914641. DOI: 10.1128/AAC.03130-15. View

14.

Andres M, Viejo-Diaz M, Fierro J . Human lactoferrin induces apoptosis-like cell death in Candida albicans: critical role of K+-channel-mediated K+ efflux. Antimicrob Agents Chemother. 2008; 52(11):4081-8. PMC: 2573133. DOI: 10.1128/AAC.01597-07. View

15.

Viejo-Diaz M, Andres M, Fierro J . Modulation of in vitro fungicidal activity of human lactoferrin against Candida albicans by extracellular cation concentration and target cell metabolic activity. Antimicrob Agents Chemother. 2004; 48(4):1242-8. PMC: 375254. DOI: 10.1128/AAC.48.4.1242-1248.2004. View

16.

Thornhill M . Immune mechanisms in oral lichen planus. Acta Odontol Scand. 2001; 59(3):174-7. DOI: 10.1080/000163501750266774. View

17.

Marable D, Bowers L, Stout T, Stewart C, Berg K, Sankar V . Oral candidiasis following steroid therapy for oral lichen planus. Oral Dis. 2015; 22(2):140-7. DOI: 10.1111/odi.12399. View

18.

Lodi G, Tarozzi M, Sardella A, Demarosi F, Canegallo L, Di Benedetto D . Miconazole as adjuvant therapy for oral lichen planus: a double-blind randomized controlled trial. Br J Dermatol. 2007; 156(6):1336-41. DOI: 10.1111/j.1365-2133.2007.07883.x. View

19.

Kondori N, Baltzer L, Dolphin G, Mattsby-Baltzer I . Fungicidal activity of human lactoferrin-derived peptides based on the antimicrobial αβ region. Int J Antimicrob Agents. 2010; 37(1):51-7. DOI: 10.1016/j.ijantimicag.2010.08.020. View

20.

Fernandes K, Carter D . The Antifungal Activity of Lactoferrin and Its Derived Peptides: Mechanisms of Action and Synergy with Drugs against Fungal Pathogens. Front Microbiol. 2017; 8:2. PMC: 5241296. DOI: 10.3389/fmicb.2017.00002. View